Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

STAAR Surgical Company Sees FY24 Adjusted EBITDA Of ~$36M And Adjusted EBITDA Per Diluted Share Of ~$0.70

Author: Benzinga Newsdesk | February 26, 2024 05:03pm

Outlook

The Company expects the following for fiscal year 2024:

  • Net sales of $335 million to $340 million.
  • Adjusted EBITDA of approximately $36 million and Adjusted EBITDA per diluted share of approximately $0.70.2

The outlook above contemplates EVO ICL sales growth of approximately 7% in APAC, including 10% in China; 10% growth in the Americas, including 10% in the U.S.; and EMEA sales consistent with fiscal year 2023.

Posted In: STAA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist